---
title: "Indaptus Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286561288.md"
datetime: "2026-05-15T12:02:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286561288.md)
  - [en](https://longbridge.com/en/news/286561288.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286561288.md)
---

# Indaptus Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.23, beating the estimate of USD -1.87.

EBIT: As of FY2026 Q1, the actual value is USD -2.16 M.

Indaptus Therapeutics, Inc. filed a Form 8-K on May 15, 2026, announcing a press release regarding its financial results for the quarter ended March 31, 2026, which includes business updates and forward-looking statements.

#### Operational Metrics

-   **Research and Development Expenses**: For the three months ended March 31, 2026, research and development expenses were approximately $0.5 million, a decrease of approximately $2.3 million from approximately $2.8 million in the three months ended March 31, 2025.
-   **General and Administrative Expenses**: For the three months ended March 31, 2026, general and administrative expenses were approximately $1.7 million, a decrease of approximately $0.1 million, or 5%, from approximately $1.8 million for the three months ended March 31, 2025.

#### Net Loss

-   Indaptus Therapeutics, Inc. reported a net loss of approximately - $2.5 million for the three months ended March 31, 2026, compared with a net loss of approximately - $4.5 million for the three months ended March 31, 2025.

#### Cash and Cash Equivalents

-   As of March 31, 2026, Indaptus Therapeutics, Inc. had cash and cash equivalents of approximately $1.5 million, a decrease from approximately $8.5 million as of December 31, 2025.

#### Cash Flow

-   **Net Cash Used in Operating Activities**: For the three months ended March 31, 2026, net cash used in operating activities was approximately - $7.0 million, an increase from net cash used in operating activities of approximately - $5.0 million for the three months ended March 31, 2025.
-   **Net Cash Provided by Financing Activities**: There was no net cash provided by financing activities during the three months ended March 31, 2026, compared with approximately $3.2 million for the three months ended March 31, 2025.

#### Unique Metrics

-   **Preferred Stock Conversion**: During the first quarter of 2026, all outstanding shares of Indaptus Therapeutics, Inc.’s Series AA Preferred Stock and Series AAA Preferred Stock were converted into shares of common stock.
-   **Warrant Repricing**: The change in other income (expense) for the three months ended March 31, 2026, included a - $410,154 impact from warrant repricing.

#### Outlook / Guidance

Indaptus Therapeutics, Inc. is currently evaluating its Decoy platform and reassessing its development priorities, operating initiatives, and resource allocation. The Company continues to assess financing alternatives and strategic options, acknowledging the need to raise additional capital to support its business objectives. Future development or collaborative opportunities will be assessed based on scientific validation, clinical and regulatory considerations, resource availability, and overall development planning.

### Related Stocks

- [INDP.US](https://longbridge.com/en/quote/INDP.US.md)

## Related News & Research

- [Yext to Announce First Quarter Fiscal Year 2027 Financial Results on June 2, 2026 | YEXT Stock News](https://longbridge.com/en/news/286970613.md)
- [Curanex Reports GMP, Toxicology Milestones as Phyto-N Readies for Q4 2026 IND](https://longbridge.com/en/news/286424596.md)
- [Richards Group Inc. Announces May 2026 Dividend | RPKIF Stock News](https://longbridge.com/en/news/286925142.md)
- [Auburn National Bancorporation declares $0.27 quarterly dividend payable June 25](https://longbridge.com/en/news/286281680.md)
- [Home Depot Was Once My Greatest Investment, But Now It's a Flaming Mess](https://longbridge.com/en/news/286951517.md)